Past, Present and the Future of Immunotherapy (Hyposensitization) in Extrinsic Atopic Bronchial Asthma

Arman Poluman


DOI: In specific therapy of extrinsic bronchial asthmatic cases, in which the atopic character is well identified with early type skin test positivity against external allergens and increased serum IgE levels, the elimination of responsible allergens seems practically impossible. That is why the concept of allergen immunotherapy (hyposensitization) has been developed at the beginning of 20th century.

In classical application (conventional systemic immunotherapy), the dosage of aqueus allergen solutions is increased at weekly inrervals until the maximum tolerated dosage (MTD) is reached. Then the therapy continues at MTD for 2-3 years.

In order to shorten the long lasting therapy "Rush" or "Clusler" treatment regimes have been developed and depot extract contained preparates are widely used.

Clinically, the effect of immunotherapy is mostly observed by the improvement in symptoms and signs. The decrease in reactivity in skin and bronchial provocation tests and the effect of suppression are observed in some immuno-serologic tests.

On the other hand, with the use of non-antigenic materials and modified allergen extracts helping IgE suppression in the extrinsic atopic bronchial asthma is believed to be an effective, thrusting, low-costing and fast-recovering treatment method in the years ahead.


Immunotherapy; Bronchial Asthma

Full Text:



Islamic Medical Association of North America (IMANA) | JIMA and IMANA on Twitter


Creative Commons License
This work by Work's author(s) is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.